Bayer proposes higher-than-expected dividend; J&J takes $100M charge on Venezuelan currency;

@FiercePharma: Teva UK pulls batches of generic Clarinex on impurities in tablets. More | Follow @FiercePharma

@EricPFierce: Capsule maker Qualicaps expanding in NC as it transitions to new ownership. News | Follow @EricPFierce

@AlisonBFierce: Dynavax will shoot for a limited approval of hep B vaccine Heplisav. The FDA nixed the product over safety issues. Report | Follow @AlisonBFierce

> Bayer plans a dividend of €1.90 ($2.51) per share, higher than the €1.82 ($2.38) expected by analysts. Report

> Johnson & Johnson ($JNJ) will take a $100 million charge against first-quarter profits because of Venezuela's currency devaluation. Report

> Amarin ($AMRN) asked the FDA to approve a new use for its blood-lipid treatment Vascepa, derived from fish oil. Release

> Fresenius Kabi's injectable drugs business is giving its parent company a boost; Fresenius SE expects 2013 profits to top €1 billion ($1.31 billion) on the unit's growth. Report

> Nestlé's health science unit bought the "medical foods" firm Pamlab, which makes products for patients with conditions such as diabetes, dementia and depression. Report

> Chemerix tapped former Glaxo Holdings CEO Ernest Mario to be chairman of the board. Report

> Mylan ($MYL) launched its version of AbbVie's ($ABBV) Tricor, a cholesterol fighter known generically as fenofibrate. Report

Medical Device News

 @FierceMedDev: NeuroPace wins FDA panel vote for epilepsy implant. More | Follow @FierceMedDev

 @MarkHFierce: A blood Dx to determine suicide risk? It's possible, and researchers will have a test ready for trials in a year. Story | Follow @MarkHFierce

 @DamianFierce: J&J has to fork over $3.4M in its first vaginal mesh verdict. Roughly 2,100 more lawsuits to go. Report | Follow @DamianFierce

> Abbott lops off another 450 jobs at stent plant. Article

> Mindray milestone: $1B in revenue in 2012. Item

> TearScience wins $70M funding commitment for dry eye device. Story

Biotech News

 @FierceBiotech: AstraZeneca claims PhIII sweep for OIC drug as CV concerns linger. News | Follow @FierceBiotech

@JohnCFierce: Officials prepare to dismantle patent rules that stifle drug R&D. Report | Follow @JohnCFierce

@RyanMFierce: Miami biotech Brickell revealed $7M B round for dermatology drug development. Florida a good spot for this company? Release | Follow @RyanMFierce

> Sanofi's Zerhouni, analysts warn sequestration could cripple R&D. Article

> Cosmetics group leads $7M round for dermatology upstart Brickell. Story

Biotech Research News

@EmilyMFierce: Retargeted bird virus could provide new treatment for prostate cancer. News | Follow @EmilyMFierce

> Therapeutic could heal wounds faster. Story

> New drug combo stops head and neck cancer in mice. Report

> Facebook, Google founders award $33M to life scientists. Item

> Obama administration plans brain-mapping project. More

Pharma Manufacturing News

> Teva repeats recall after getting batch numbers wrong. More

> Affymax explores manufacturing for ties to fatal drug reactions. Story

> Qualicaps expanding plant as Mitsubishi takes ownership. News

> Manufacturing continues to undercut Ranbaxy. Article

And Finally... Just one week of poor sleep can cause genetic changes that might lead to disease. Report

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.